Navigation Links
Brookdale Announces Third Quarter 2007 Results
Date:11/7/2007

eds of $140.0 million.

CHICAGO, Nov. 7 /PRNewswire-FirstCall/ -- Brookdale Senior Living Inc. (NYSE: BKD) (the "Company") today reported financial results for the third quarter of 2007. Net loss for the quarter and nine months ended September 30, 2007 was $(58.9) million and $(112.7) million, respectively, or $(0.58) and $(1.11) per diluted common share. The losses include non-cash items for depreciation and amortization, non-cash compensation expense and straight-line lease expense, net of deferred gain amortization, which totaled $92.9 million and $281.3 million, respectively.

Mark J. Schulte, Brookdale's Co-CEO, said, "Despite the challenging economic environment, our third quarter CFFO per share increased 59% and same store Facility Operating Income grew 8.2% over the same period last year. We believe that even with flat occupancy, Brookdale can achieve annual organic growth in CFFO per share of approximately 20%, and in addition to its dividend provide shareholders with an attractive total return."

As a dividend-paying company, Brookdale's management utilizes Adjusted EBITDA and Cash From Facility Operations to evaluate the Company's performance and liquidity because these metrics exclude non-cash expenses such as depreciation and amortization, non-cash compensation expense and straight-line lease expense, net of deferred gain amortization. Brookdale also uses Facility Operating Income to assess the performance of its facilities.

For the quarter and nine months ended September 30, 2007, Adjusted EBITDA was $83.6 million and $237.0 million, respectively. Facility Operating Income was $162.8 million and $489.2 million for the quarter and nine month period ended September 30, 2007, respectively.


'/>"/>
SOURCE Brookdale Senior Living Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Brookdale Announces Third Quarter Common Stock Dividend of $0.50
2. Brookdale Announces Third Quarter 2007 Release and Earnings Call
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Dynatronics Receives 180-Day NASDAQ Extension 2Nearly 100 HIV/AIDS Drugs and Vaccines in Development Pipeline 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 1NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 2NxStage Extends Supply Agreement with B Braun Medical Inc to Include Streamline 28R 29 Technology 47454 3AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 1AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 2AGA Institute and Horizon Therapeutics Launch Connect to Protect Program to Educate Physicians and Consumers on Risks Associated With NSAID Use 12385 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 1Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 2Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 3Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 4Shire Presented Results of a New Database Analysis on Lialda 28R 29 28Mesalamine 29 and Other 5 ASAs for Ulcerative Colitis at Digestive Disease Week 4503 5